In a patient-derived xenograft model, HMucBOT-1 retained MBOT morphology, whereas HMucBOT-2 exhibited features of mucinous carcinoma with undifferentiated components, with unique genetic alterations, including KRAS amplification. The gene discussed is KRAS; the disease is mucinous adenocarcinoma.